The original use of Raloxifene 60 mg tablet is as a medication for the prevention and treatment of osteoporosis in postmenopausal women. It works by mimicking the effects of estrogen in some tissues while blocking estrogen's effects in others, thereby helping to maintain bone density and reduce the risk of fractures. Additionally, raloxifene has been approved for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer.
Raloxifene was initially developed as a selective estrogen receptor modulator (SERM) primarily for the prevention and treatment of osteoporosis in postmenopausal women. Osteoporosis is a condition characterized by decreased bone density, which increases the risk of fractures, particularly in older women after menopause due to declining estrogen levels.